UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 278

Sortiert nach

From little subclones grow mighty oaks

Nature reviews. Clinical oncology, 2023-03, Vol.20 (3), p.141-142

2023

Volltextzugriff (PDF)

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma

Nature communications, 2021-01, Vol.12 (1), p.293-13, Article 293

2021

Volltextzugriff (PDF)

BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma

Clinical cancer research, 2020-05, Vol.26 (10), p.2422-2432

2020

Volltextzugriff (PDF)

Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma

Clinical cancer research, 2024-02, Vol.30 (3), p.575

2024

Volltextzugriff (PDF)

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

Journal of clinical oncology, 2015-11, Vol.33 (33), p.3911-3920

2015

Volltextzugriff (PDF)

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma

Blood, 2017-05, Vol.129 (18), p.2471-2478

2017

Volltextzugriff (PDF)

Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma

Nature communications, 2021-08, Vol.12 (1), p.5172-5172, Article 5172

2021

Volltextzugriff (PDF)

Multiparameter flow cytometry in plasma cell disorders: when in doubt, go with the flow

British journal of haematology, 2022-03, Vol.196 (5), p.1132-1133

2022

Volltextzugriff (PDF)

Daratumumab is effective in the relapsed or refractory systemic light‐chain amyloidosis but associated with high infection burden in a frail real‐life population

British journal of haematology, 2020-02, Vol.188 (3), p.e24-e27

2020

Volltextzugriff (PDF)

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

Nature communications, 2015-04, Vol.6 (1), p.6997-6997, Article 6997

2015

Volltextzugriff (PDF)

The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma

Haematologica (Roma), 2017-09, Vol.102 (9), p.1617

2017

Volltextzugriff (PDF)

Monitoring minimal residual disease in the bone marrow using next generation sequencing

Best practice & research. Clinical haematology, 2020-03, Vol.33 (1), p.101149-101149, Article 101149

2020

Volltextzugriff (PDF)

Reconstructing the evolutionary history of multiple myeloma

Best practice & research. Clinical haematology, 2020-03, Vol.33 (1), p.101145-101145, Article 101145

2020

Volltextzugriff (PDF)

Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients

Leukemia, 2022-03, Vol.36 (3), p.613-624

2022

Volltextzugriff (PDF)

The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma

Clinical cancer research, 2016-12, Vol.22 (23), p.5783-5794

2016

Volltextzugriff (PDF)

Bartonellosis mimicking post-transplant lymphoproliferative diseases

Nephrology, dialysis, transplantation, 2022-02, Vol.37 (3), p.599-601

2022

Volltextzugriff (PDF)

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes

Nature communications, 2022-06, Vol.13 (1), p.3449-3449, Article 3449

2022

Volltextzugriff (PDF)

Chromothripsis as a pathogenic driver of multiple myeloma

Seminars in cell & developmental biology, 2022-03, Vol.123, p.115-123

2022

Volltextzugriff (PDF)

Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series

Neurology, 2017-01, Vol.88 (1), p.101

2017

Volltextzugriff (PDF)

Revealing the impact of structural variants in multiple myeloma

Blood cancer discovery, 2020-11, Vol.1 (3), p.258

2020

Volltextzugriff (PDF)

Patient experiences of referral practices and primary care physiotherapy for chronic nonspecific low back pain

Physiotherapy theory and practice, 2024-06, Vol.40 (6), p.1326-1342

2024

Volltextzugriff (PDF)

Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)

European journal of haematology, 2021-09, Vol.107 (3), p.370-373

2021

Volltextzugriff (PDF)

A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma

Scientific reports, 2021-03, Vol.11 (1), p.7009-9, Article 7009

2021

Volltextzugriff (PDF)

1 – 25 von 278

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(258)
Mit Volltextzugriff
(246)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(71)
Clinical Lymphoma, Myeloma And Leukemia
(11)
British Journal Of Haematology
(8)
Journal Of Clinical Oncology
(8)
Plos One
(8)
Clinical Cancer Research
(7)
Nature Communications
(7)
Leukemia
(6)
Archives Of Ophthalmology
(5)
Hématologie
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

From little subclones grow mighty oaks

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma

BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma

Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma

Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma

Multiparameter flow cytometry in plasma cell disorders: when in doubt, go with the flow

Daratumumab is effective in the relapsed or refractory systemic light‐chain amyloidosis but associated with high infection burden in a frail real‐life population

Accelerated single cell seeding in relapsed multiple myeloma

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma

Monitoring minimal residual disease in the bone marrow using next generation sequencing

Reconstructing the evolutionary history of multiple myeloma

Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients

The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma

Bartonellosis mimicking post-transplant lymphoproliferative diseases

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes

Genomic Classification and Individualized Prognosis in Multiple Myeloma

Chromothripsis as a pathogenic driver of multiple myeloma

Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series

Revealing the impact of structural variants in multiple myeloma

Patient experiences of referral practices and primary care physiotherapy for chronic nonspecific low back pain

Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)

A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma

Suchergebnisse filtern